Guelpa G
Hôpital de la Providence, Service de médecine, Neuchâtel.
Praxis (Bern 1994). 2000 Aug 24;89(34):1331-8.
The inhibitors of the angiotensin-converting-enzyme (ACEI) are considered as the best pharmacological class for the treatment of patients with diabetic nephropathy. Independently of lowering the arterial blood pressure they reduce the proteinuria and slow the evolution of the renal failure. Calcium-channels blockers not belonging to the dehydropyridine-type (verapamil-diltiazem) possess some of these features, too, contrarily to the rest of calcium-antagonists (nifedipine-like). Two clinical studies dealing with type-II diabetic-patients whose nephropathy was complicated by a nephrotic syndrome and a rapid progressive renal failure showed that the combination of verapamil with an ACEI, further dietetic measures (protein restriction, saltless diet), permitted a significant decrement of the proteinuria as well as a stabilisation of the kidney function. This effect could not be shown under treatment with only ACEI. Thus the proteinuria-inhibiting and kidney-protecting effects of the combination of theses two substances-groups should be known when the physician is confronted at this clinical situation that determines the prognostic of the kidney function in such a dramatic way and short laps of time.
血管紧张素转换酶抑制剂(ACEI)被认为是治疗糖尿病肾病患者的最佳药物类别。除了降低动脉血压外,它们还能减少蛋白尿并减缓肾衰竭的进展。不属于二氢吡啶类的钙通道阻滞剂(维拉帕米 - 地尔硫䓬)也具有其中一些特性,这与其他钙拮抗剂(硝苯地平类)相反。两项针对Ⅱ型糖尿病患者的临床研究表明,这些患者的肾病并发肾病综合征和快速进行性肾衰竭,维拉帕米与ACEI联合使用,再加上进一步的饮食措施(蛋白质限制、无盐饮食),可使蛋白尿显著减少,肾功能稳定。仅使用ACEI治疗时未显示出这种效果。因此,当医生面对这种以如此戏剧性的方式并在短时间内决定肾功能预后的临床情况时,应该了解这两类物质联合使用的蛋白尿抑制和肾脏保护作用。